Could GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound be far more than weight-loss drugs? In this special bonus episode of Greta Wire, Greta Van Susteren is joined by Dr. Jen Ashton on NEWSMAX TV’s The Record with Greta Van Susteren to discuss a new study suggesting GLP-1 drugs may be associated with reduced cancer progression in several obesity-related cancers. Dr. Ashton explains what the study found, what it does — and does not — prove, and why researchers are now looking at GLP-1 medications for possible effects on inflammation, the immune system, cancer spread, recurrence, and prevention. Greta also presses on the insurance question: if these drugs may help prevent expensive and devastating medical complications,…
Next month's launch of a Medicare program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound and other blockbuster treatments — and create new bottlenecks at doctors' offices. The big picture: It could become one of the biggest drug rollouts ever — and it could test an already burdened system as seniors seek new GLP-1 prescriptions. - Clinicians worry that could also give short shrift to patient counseling on how to take the injectables and pills, adjust dosages and deal with side effects. - Medicare has been prohibited by law from covering weight-loss drugs. Where it stands: The new program is part of a deal President Trump struck with Eli Lilly and Novo Nordisk to cut prices for…
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message.
Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.
Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few pounds.
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.
